Abstract：
This study aimed to determine the clinicopathological predictive factors of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), and nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFH, AI-type). In this single-centered, retrospective study, medical records of 59 patients who were diagnosed with PTCL, NOS, or nTFH, AI-type from March 2007 to September 2022 were reviewed. The clinicopathological variables, including immunohistochemistry(IHC) subgroups, distinguishing TBX21 from the GATA3 subgroups were analyzed. Overall, 28 patients (75.7%) in the TBX21 group were PTCL, NOS. There were 9 (24.3%) patients in the GATA3 group. In univariable analyses, lymphoma subtype, age, and performance status were associated with progression-free survival (PFS), and overall survival (OS). In multivariable analyses, lymphoma subtype, and performance status were related to PFS and OS (P = 0.012, P < 0.001, P = 0.006, and P < 0.001, respectively). The GATA3 subgroup tended to have a worse prognosis in univariable analyses; however, it became more insignificant in multivariable when lymphoma subtype and performance status were adjusted (P = 0.065, P = 0.180, P = 0.972, and P = 0.265, respectively). The double-positive group showed variable prognoses of better PFS and worse OS. PD-1 and PD-L1 were associated with the EBV in situ hybridization (P = 0.027, and P = 0.005), and PD-1 was associated with CD30 expression (P = 0.043). This study demonstrated the potential of IHC classification to predict prognosis for PTCL, NOS, as well as nTFH AI-type, although further validation is necessary. Treatments targeting CD30, PD-1, and PD-L1 appear promising for lymphoma treatment.
摘要：
本研究旨在确定外周T细胞淋巴瘤的临床病理预测因素。未指定(PTCL，NOS),结性T滤泡辅助细胞淋巴瘤,血管免疫母细胞型（nTFH，AI型）。在这个单一的中心，回顾性研究,59名诊断为PTCL的患者的医疗记录，NOS,或nTFH，回顾了2007年3月至2022年9月的AI类型。临床病理变量，包括免疫组织化学（IHC）亚组，分析了TBX21与GATA3亚组的区别.总的来说,TBX21组28例(75.7%)患者行PTCL,NOS.GATA3组有9例(24.3%)患者。在单变量分析中，淋巴瘤亚型,年龄,和表现状态与无进展生存期（PFS）相关，总生存率（OS）。在多变量分析中，淋巴瘤亚型,和表现状态与PFS和OS相关（分别为P=0.012，P<0.001，P=0.006和P<0.001）。在单变量分析中，GATA3亚组的预后往往较差；然而，当调整淋巴瘤亚型和表现状态时,其在多变量中变得更加不显著(分别为P=0.065,P=0.180,P=0.972和P=0.265).双阳性组表现出不同的预后，即PFS较好，OS较差。PD-1和PD-L1与EBV原位杂交相关(P=0.027,P=0.005),PD-1与CD30表达相关(P=0.043)。这项研究证明了IHC分类预测PTCL预后的潜力，NOS,以及nTFHAI型，虽然进一步验证是必要的。靶向CD30、PD-1和PD-L1的治疗对于淋巴瘤治疗似乎是有希望的。
